[go: up one dir, main page]

WO2002074735A3 - Biurethanderivate - Google Patents

Biurethanderivate Download PDF

Info

Publication number
WO2002074735A3
WO2002074735A3 PCT/EP2002/002095 EP0202095W WO02074735A3 WO 2002074735 A3 WO2002074735 A3 WO 2002074735A3 EP 0202095 W EP0202095 W EP 0202095W WO 02074735 A3 WO02074735 A3 WO 02074735A3
Authority
WO
WIPO (PCT)
Prior art keywords
biurethane
derivatives
tumours
prophylaxis
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/002095
Other languages
English (en)
French (fr)
Other versions
WO2002074735A2 (de
Inventor
Werner Mederski
Bertram Cezanne
Dieter Dorsch
Christos Tsaklakidis
Johannes Gleitz
Christopher Barnes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to CA002441427A priority Critical patent/CA2441427A1/en
Priority to MXPA03008394A priority patent/MXPA03008394A/es
Priority to EP02722151A priority patent/EP1385818A2/de
Priority to US10/472,084 priority patent/US6943179B2/en
Priority to JP2002573744A priority patent/JP2004531494A/ja
Priority to HU0303512A priority patent/HUP0303512A2/hu
Publication of WO2002074735A2 publication Critical patent/WO2002074735A2/de
Anticipated expiration legal-status Critical
Publication of WO2002074735A3 publication Critical patent/WO2002074735A3/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Neue Verbindungen der Formel (I) worin X, Y, Z, R, R?1, R2, R3¿ die in Patentanspruch 1 angegebene Bedeutung haben, sind Inhibitoren des Koagulationsfaktors Xa und können zur Prophylaxe und/oder Therapie von tromboembolischen Erkrankungen und zur Behandlung von Tumoren eingesetzt werden.
PCT/EP2002/002095 2001-03-20 2002-02-27 Biurethanderivate Ceased WO2002074735A2 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002441427A CA2441427A1 (en) 2001-03-20 2002-02-27 Biurethane derivatives
MXPA03008394A MXPA03008394A (es) 2001-03-20 2002-02-27 Derivados de biuretano.
EP02722151A EP1385818A2 (de) 2001-03-20 2002-02-27 Biurethanderivate
US10/472,084 US6943179B2 (en) 2001-03-20 2002-02-27 Biurethane derivatives
JP2002573744A JP2004531494A (ja) 2001-03-20 2002-02-27 ビウレタン誘導体
HU0303512A HUP0303512A2 (hu) 2001-03-20 2002-02-27 Biuretánszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10113402A DE10113402A1 (de) 2001-03-20 2001-03-20 Biurethanderivate
DE10113402.9 2001-03-20

Publications (2)

Publication Number Publication Date
WO2002074735A2 WO2002074735A2 (de) 2002-09-26
WO2002074735A3 true WO2002074735A3 (de) 2003-11-27

Family

ID=7678165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/002095 Ceased WO2002074735A2 (de) 2001-03-20 2002-02-27 Biurethanderivate

Country Status (10)

Country Link
US (1) US6943179B2 (de)
EP (1) EP1385818A2 (de)
JP (1) JP2004531494A (de)
CN (1) CN1498206A (de)
CA (1) CA2441427A1 (de)
DE (1) DE10113402A1 (de)
HU (1) HUP0303512A2 (de)
MX (1) MXPA03008394A (de)
WO (1) WO2002074735A2 (de)
ZA (1) ZA200308060B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031145A2 (en) * 2002-10-02 2004-04-15 Bristol-Myers Squibb Company Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibitors
DE10302500A1 (de) * 2003-01-23 2004-07-29 Merck Patent Gmbh Carbonsäureamidderivate
US7205318B2 (en) * 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
WO2004087696A1 (de) * 2003-04-03 2004-10-14 Merck Patent Gmbh Pirazolidin-1,2-dicarbonsaüre-1-((phenyl)-amid)-2-((phenyl)-amid) derivate als koagulationsfaktor xa inhibitoren zur behandlung von thrombosen
KR20050118708A (ko) 2003-04-03 2005-12-19 메르크 파텐트 게엠베하 혈전-색전 질환의 치료에서 응고 인자 ｘａ의 저해제로서사용하기 위한피롤리디노-１,２-디카르복시-１-(페닐아미드)-２-(４-(３-옥소-모르폴리노-４-일)-페닐아미드) 유도체 및 관련화합물
JP4769082B2 (ja) 2003-12-17 2011-09-07 武田薬品工業株式会社 ウレア誘導体、その製造法及び用途
DE102004004731A1 (de) * 2004-01-30 2005-08-18 Merck Patent Gmbh Harnstoffderivate
US7371743B2 (en) 2004-02-28 2008-05-13 Boehringer Ingelheim International Gmbh Carboxylic acid amides, the preparation thereof and their use as medicaments

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0790240A1 (de) * 1996-02-15 1997-08-20 Tanabe Seiyaku Co., Ltd. Phenol-Derivate mit pharmazeutischer Aktivität und Verfahren zu ihrer Herstellung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0790240A1 (de) * 1996-02-15 1997-08-20 Tanabe Seiyaku Co., Ltd. Phenol-Derivate mit pharmazeutischer Aktivität und Verfahren zu ihrer Herstellung

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAIN B F ET AL: "POTENTIAL ANTITUMOUR AGENTS. X. BISQUATERNARY SALTS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 12, no. 2, March 1969 (1969-03-01), pages 199 - 206, XP001074169, ISSN: 0022-2623 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; UTSUMI, NAOSHI ET AL: "Production of foamy material", XP002241532, retrieved from STN Database accession no. 80:71652 CA *
KHAU, VIEN V. ET AL: "1,3-Dipolar cycloreversion of a 1,3,4-oxadiazolidine as a controlled azomethine imine surrogate for pyrazolidine synthesis", TETRAHEDRON LETTERS (1996), 37(25), 4323-4326, 1996, XP004029149 *
ZINNER, G. ET AL: "Carbamoylation of hydrazine derivatives", ARCHIV DER PHARMAZIE (WEINHEIM, GERMANY) (1973), 306(1), 35-44, 1973, XP008017539 *

Also Published As

Publication number Publication date
ZA200308060B (en) 2004-07-23
CN1498206A (zh) 2004-05-19
US6943179B2 (en) 2005-09-13
EP1385818A2 (de) 2004-02-04
WO2002074735A2 (de) 2002-09-26
US20040097550A1 (en) 2004-05-20
JP2004531494A (ja) 2004-10-14
CA2441427A1 (en) 2002-09-26
MXPA03008394A (es) 2004-01-29
HUP0303512A2 (hu) 2004-01-28
DE10113402A1 (de) 2002-09-26

Similar Documents

Publication Publication Date Title
ZA200306419B (en) Phenyl derivatives.
MY140031A (en) Carbonyl compounds
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
EP1450808B8 (de) Quinazolinderivate für die behandlung durch t-zellen vermittelter krankheiten
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
WO2002096905A8 (en) Thiazole compounds useful as inhibitors of protein kinases
GEP20063805B (en) Alkyne-Arylnaphthyridin-4-one as Phosphodiesterase-4 Inhibitors
TR200302242T2 (tr) Protein kinaz önleyicileri olarak pirolopirimidinler
AU2003226572A1 (en) Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors
TW200504012A (en) Ethynylproline derivatives
WO2000040583A3 (de) Imidazo[4,5-c]-pyridin-4-on-derivate
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
AU2001264065A1 (en) Serine protease inhibitors
WO2004002477A8 (de) 2-(phenyl)-2h-pyrazol-3-carbonsäure-n-4-(thioxo-heterocyclyl)-phenyl-amid derivate und entsprechende imino-heterocyclyl derivate sowie verwandte verbindungen als inhibitoren der koagulationsfaktoren xa und/oder viia zur behandlung bon thrombosen
CA2461622A1 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
AU2001264081A1 (en) Serine protease inhibitors
SE0302756D0 (sv) Novel Compounds
UA85676C2 (en) Carbonyl compounds
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
SE9803773D0 (sv) Compounds
MXPA04005809A (es) Inhibidores de proteinas quinasas.
WO2002074735A3 (de) Biurethanderivate
MXPA03010205A (es) Derivados de acido oxalico.
EP1304111A3 (de) Verwendung von Methylol-enthaltenden Verbindungen zur Behandlung von Brustkrebs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002722151

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/008394

Country of ref document: MX

Ref document number: 10472084

Country of ref document: US

Ref document number: 028067584

Country of ref document: CN

Ref document number: 2002253080

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2441427

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002573744

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003/08060

Country of ref document: ZA

Ref document number: 200308060

Country of ref document: ZA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002722151

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002722151

Country of ref document: EP